Abstract
Background
COVID-19 caused by SARS-CoV-2 ranges from asymptomatic to severe disease and can cause fatal and devastating outcome in many cases. In this study, we have compared the clinical, biochemical and immunological parameters across the different disease spectrum of COVID-19 in Bangladeshi patients.
Methodology/Principal findings
This longitudinal study was conducted in two COVID-19 hospitals and also around the community in Dhaka city in Bangladesh between November 2020 to March 2021. A total of 100 patients with COVID-19 infection were enrolled and classified into asymptomatic, mild, moderate and severe cases (n = 25/group). In addition, thirty age and sex matched healthy participants were enrolled and 21 were analyzed as controls based on exclusion criteria. After enrollment (study day1), follow-up visits were conducted on day 7, 14 and 28 for the cases.
Older age, male gender and co-morbid conditions were the risk factors for severe COVID-19 disease. Those with moderate and severe cases of infection had low lymphocyte counts, high neutrophil counts along with a higher neutrophil-lymphocyte ratio (NLR) at enrollment; this decreased to normal range within 42 days after the onset of symptom. At enrollment, D-dimer, CRP and ferritin levels were elevated among moderate and severe cases. The mild, moderate, and severe cases were seropositive for IgG antibody by day 14 after enrollment. Moderate and severe cases showed significantly higher IgM and IgG levels of antibodies to SARS-CoV-2 compared to mild and asymptomatic cases.
Conclusion/Significance
We report on the clinical, biochemical, and hematological parameters associated with the different severity of COVID-19 infection. We also show different profile of antibody response against SARS-CoV-2 in relation to disease severity, especially in those with moderate and severe disease manifestations compared to the mild and asymptomatic infection.
Funder
Bill and Melinda Gates Foundation
Publisher
Public Library of Science (PLoS)
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health
Reference44 articles.
1. Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh;T Shirin;Int J Infect Dis,2020
2. Genomic and mobility data reveal mass population movement as a driver of SARS-CoV-2 dissemination and diversity in Bangladesh;LA Cowley;medRxiv,2021
3. Nearly 20 lakh Dhaka residents could be Covid-19 positive, 78% asymptomatic: study. The Daily Star. 11 Aug 2020. https://www.thedailystar.net/coronavirus-deadly-new-threat/news/nearly-20-lakh-dhaka-residents-could-be-covid-19-positive-78-asymptomatic-study-1942953. Accessed 26 Aug 2020.
4. WHO Coronavirus (COVID-19) Dashboard. [cited 20 May 2021]. https://covid19.who.int
5. Bangladesh COVID-19 Hospital Information. 17 Aug 2020 [cited 17 Aug 2020]. https://dghs.gov.bd/images/docs/Notice/2020/corona/covid19_hospital_information.pdf